<SEC-DOCUMENT>0001213900-17-000257.txt : 20170111
<SEC-HEADER>0001213900-17-000257.hdr.sgml : 20170111
<ACCEPTANCE-DATETIME>20170111172812
ACCESSION NUMBER:		0001213900-17-000257
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170111
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170111
DATE AS OF CHANGE:		20170111

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OptimizeRx Corp
		CENTRAL INDEX KEY:			0001448431
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-BUSINESS SERVICES, NEC [7389]
		IRS NUMBER:				261265381
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-53605
		FILM NUMBER:		17523583

	BUSINESS ADDRESS:	
		STREET 1:		400 WATER ST., STE. 200
		CITY:			ROCHESTER
		STATE:			MI
		ZIP:			48307
		BUSINESS PHONE:		248-651-6558

	MAIL ADDRESS:	
		STREET 1:		400 WATER ST., STE. 200
		CITY:			ROCHESTER
		STATE:			MI
		ZIP:			48307
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k011017_optimizerx.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>WASHINGTON, D.C. 20549<BR>
____________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.25in; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B><BR>
<BR>
Date of Report (Date of earliest event reported): January 11, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><BR>
<U>OptimizeRx Corporation</U><BR>
(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-decoration: none; text-transform: none; vertical-align: baseline"><FONT STYLE="font-variant: normal; text-transform: none; vertical-align: baseline">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt; font-variant: normal; text-decoration: none; text-transform: none; vertical-align: baseline">
<TR STYLE="vertical-align: baseline; font-variant: normal; text-decoration: none; text-transform: none">
    <TD STYLE="width: 35%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: none; text-align: center; font-variant: normal; text-transform: none; vertical-align: baseline; border-bottom: Black 1pt solid"><FONT STYLE="font-variant: normal; text-transform: none; vertical-align: baseline">Nevada</FONT></TD>
    <TD STYLE="width: 1%; font-variant: normal; text-decoration: none; text-transform: none; vertical-align: baseline; padding-bottom: 1pt"><FONT STYLE="font-variant: normal; text-transform: none; vertical-align: baseline">&nbsp;</FONT></TD>
    <TD STYLE="width: 28%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: none; text-align: center; font-variant: normal; text-transform: none; vertical-align: baseline; border-bottom: Black 1pt solid"><FONT STYLE="font-variant: normal; text-transform: none; vertical-align: baseline">000-53605</FONT></TD>
    <TD STYLE="width: 1%; font-variant: normal; text-decoration: none; text-transform: none; vertical-align: baseline; padding-bottom: 1pt"><FONT STYLE="font-variant: normal; text-transform: none; vertical-align: baseline">&nbsp;</FONT></TD>
    <TD STYLE="width: 35%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: none; text-align: center; font-variant: normal; text-transform: none; vertical-align: baseline; border-bottom: Black 1pt solid"><FONT STYLE="font-variant: normal; text-transform: none; vertical-align: baseline">26-1265381</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(State or other jurisdiction of incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(I.R.S. Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 64%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: none; text-align: center; font-variant: normal; text-transform: none; vertical-align: baseline; border-bottom: Black 1pt solid"><FONT STYLE="font-variant: normal; text-transform: none; vertical-align: baseline">400
    Water Street, Suite 200, Rochester, MI</FONT></TD>
    <TD STYLE="width: 1%; font-variant: normal; text-decoration: none; text-transform: none; vertical-align: baseline; padding-bottom: 1pt"><FONT STYLE="font-variant: normal; text-transform: none; vertical-align: baseline">&nbsp;</FONT></TD>
    <TD STYLE="width: 35%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: none; text-align: center; font-variant: normal; text-transform: none; vertical-align: baseline; border-bottom: Black 1pt solid"><FONT STYLE="font-variant: normal; text-transform: none; vertical-align: baseline">48307</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Address of principal executive offices)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Registrant&rsquo;s telephone number, including area code: <U>248-651-6568</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;___________________________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Former name or former address, if changed since
        last report)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT>&#9744;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT>&#9744;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>SECTION 8 &ndash; Other Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 8.01&#9;Other Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On January 11, 2017, we issued a press release concerning our invitation
to present at the Noble Capital Markets&rsquo; 13th Annual Investor Conference. A copy of the press release is attached as Exhibit
99.1 to this Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The information in Item 8.01 of this Current
Report on Form 8-K (including Exhibit 99.1) shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Securities
Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;) or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth
by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>SECTION 9 &ndash; Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 9.01&#9;Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left; background-color: rgb(204,238,255)">
    <TD STYLE="width: 7%">99.1</TD>
    <TD STYLE="width: 93%">Press release, dated January 11, 2017&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>OptimizeRx Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; padding-right: 5.4pt; border-bottom: Black 1pt solid; text-decoration: none; font-variant: normal; text-transform: none; vertical-align: baseline; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/
    Doug Baker</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; text-align: left">Doug Baker<BR>
Chief Financial Officer</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: January 11, 2017</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>



<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: center; margin-top: 3pt; margin-bottom: 3pt">2<DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>f8k011017ex99i_optimizerx.htm
<DESCRIPTION>PRESS RELEASE DATED JANUARY 11, 2017
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 87px; width: 348px"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 14pt 0; text-align: center; background-color: white; color: #333333"><FONT STYLE="color: Black"><B>OptimizeRx
to Present at Noble Capital Markets&rsquo; 13<SUP>th</SUP> Annual Investor Conference on January 30, 2017</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 7.5pt; background-color: white"><B>ROCHESTER, Mich., January
11, 2017</B> -- OptimizeRx Corp. (OTCQB: OPRX), a health technology software company whose premier content-delivery platform enables
pharmaceutical companies to offer doctors valuable brand messaging information and patient support right at point of prescribe,
has been invited to present at the NobleCon13 - Noble Capital Markets&rsquo; 13th Annual Investor Conference being held on January
30-31, 2017 at the Boca Raton Resort &amp; Club in Boca Raton, Florida.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 7.5pt; background-color: white">OptimizeRx CEO William Febbo
is scheduled to present on Monday, January 30 at 2:30 p.m. Eastern time, with one-on-one meetings held throughout the day.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">He will discuss the company&rsquo;s recent ROI outcomes
data for its client&rsquo;s programs and the rebranding from their dominant one product, financial messaging, to multiple services
in and around point-of-care, including brand messaging and brand support. He will also provide an update on its partnership with
WPP, the largest marketing services company in the world, and the OptimizeRx vision in leading the next generation of electronic
health record (EHR) communication solutions to the market.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 7.5pt; background-color: white">A high-definition, video
webcast of OptimizeRx&rsquo;s presentation will be available at: http://noble.mediasite.com/mediasite/Play/4ee7ee409e1c4b3c82028790942d56601d
and available for replay at Noble Financial websites: www.noblecapitalmarkets.com, or www.nobleconference.com, or at OptimizeRx&rsquo;s
website in the Investors section at www.optimizerx.com.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 7.5pt; background-color: white">For more information about
the conference or to schedule a one-on-one meeting with OptimizeRx management, please contact your Noble Capital Markets representative.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white"><B>About Noble Capital Markets,
Inc.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 7.5pt; background-color: white">Noble Capital Markets, established
in 1984, is an equity-research driven, full-service, investment &amp; merchant banking boutique focused on the healthcare, media
&amp; entertainment, technology and natural resources sectors. The company has offices in Boca Raton, New York and Boston. In addition
to NobleCon - the annual multi-sector investor conference and the Media, Finance &amp; Investor Conference, produced in partnership
with the National Association of Broadcasters (NAB) and held each spring in Las Vegas, throughout the year Noble hosts numerous
&ldquo;non-deal&rdquo; corporate road shows across the United States and Canada. Members: FINRA, SIPC, MSRB. www.noblecapitalmarkets.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 7.5pt; background-color: white"><B>About OptimizeRx Corp</B><BR>
Based in Rochester, MI, OptimizeRx&nbsp;Corporation (OTCQB:OPRX) is a health technology software company that is revolutionizing
the point of care experience through technology to improve clinical decisions and outcomes. OptimizeRx&rsquo;s unique platform
help patients better afford and comply with their medicines and healthcare products, while offering pharmaceutical and healthcare
companies effective ways to expand awareness, access and adherence to their medications.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">The company&rsquo;s core product replaces drug samples
with electronic trial vouchers and copay financial message savings that are electronically added to an e-Prescription and sent
electronically to the pharmacy and is integrated within leading electronic health record (EHR) platforms in the country, including
Allscripts, Quest Diagnostics, Practice Fusion, DrFirst, New Crop and other EHRs to reach over 300,000 healthcare providers. In
turn, OptimizeRx promotes patient savings and support from the world&rsquo;s largest pharmaceutical companies, including Pfizer,
Lilly, Novartis, AstraZeneca and many others.For more information, please go to&nbsp;<FONT STYLE="color: #337AB7">www.optimizerxcorp.com</FONT>.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>Important
Cautions Regarding Forward Looking Statements</B><BR>
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as
amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make
an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements,
which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any
forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently
subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ
materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties
to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition
and other material risks.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white"><B>Company Contact:</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">OptimizeRx</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">Doug Baker, CFO</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">dbaker@optimizerx.com</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">248-651-6568 x807</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white"><B>Investor Relations Contact:</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">CMA</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">Ron Both, Senior Managing Partner</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">oprx@cma.team</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">949-432-7557</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: center; margin-top: 3pt; margin-bottom: 3pt">2<DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !7 5P# 2(  A$! Q$!_\0
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M_P!V/^9J#XP_\A?3O^N#?^A5:I0^L<MM/^ '0U=,^**MH=S>ZI#&LZ2^7#!
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MFO1?A?X?-EH+WMU'B2\<,@;KL'3\^37H2A.EA.23][_@ANS-^+-RUQIFG!E
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)** "BBB@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
